These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7492077)

  • 1. Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones.
    Takenouchi T; Ishii C; Sugawara M; Tokue Y; Ohya S
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1414-8. PubMed ID: 7492077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.
    Wang T; Tanaka M; Sato K
    Antimicrob Agents Chemother; 1998 Feb; 42(2):236-40. PubMed ID: 9527766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones.
    Takenouchi T; Sakagawa E; Sugawara M
    Antimicrob Agents Chemother; 1999 Feb; 43(2):406-9. PubMed ID: 9925546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of quinolone resistance in Staphylococcus aureus.
    Tanaka M; Wang T; Onodera Y; Uchida Y; Sato K
    J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY; Trucksis M; Hooper DC
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.
    Ozeki S; Deguchi T; Yasuda M; Nakano M; Kawamura T; Nishino Y; Kawada Y
    J Clin Microbiol; 1997 Sep; 35(9):2315-9. PubMed ID: 9276409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the DNA gyrA gene mutation with resistance to fluoroquinolones in Staphylococcus aureus isolated from patients].
    Fang Z; Song X; Liu X
    Hua Xi Yi Ke Da Xue Xue Bao; 2000 Mar; 31(1):24-6. PubMed ID: 12501604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations.
    Ouabdesselam S; Hooper DC; Tankovic J; Soussy CJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1667-70. PubMed ID: 7486897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of novel mutations in the gyrA gene of Staphylococcus aureus by nonradioisotopic single-strand conformation polymorphism analysis and direct DNA sequencing.
    Tokue Y; Sugano K; Saito D; Noda T; Ohkura H; Shimosato Y; Sekiya T
    Antimicrob Agents Chemother; 1994 Mar; 38(3):428-31. PubMed ID: 7911287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a gyrA plasmid for genetic characterization of fluoroquinolone-resistant Staphylococcus aureus.
    Tankovic J; Duval J; Courvalin P
    FEMS Immunol Med Microbiol; 1994 Jun; 9(1):35-9. PubMed ID: 7920462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A study on the resistance of Staphylococcus aureus and the mechanisms of its resistance to fluoroquinolone].
    Lei Y; Gui X; Feng G
    Zhonghua Nei Ke Za Zhi; 2001 Mar; 40(3):176-9. PubMed ID: 11798575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
    Ito H; Yoshida H; Bogaki-Shonai M; Niga T; Hattori H; Nakamura S
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2014-23. PubMed ID: 7811012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
    Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
    Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and China.
    Tanaka M; Zhang YX; Ishida H; Akasaka T; Sato K; Hayakawa I
    J Med Microbiol; 1995 Mar; 42(3):214-9. PubMed ID: 7884804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.
    Kenny GE; Young PA; Cartwright FD; Sjöström KE; Huang WM
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2493-6. PubMed ID: 10508030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.